Summary & Overview
HCPCS J9316: Injection of Pertuzumab and Trastuzumab with Hyaluronidase
HCPCS Level II code J9316 designates the injection of pertuzumab, trastuzumab, and hyaluronidase-zzxf, billed per 10 mg. This code captures a combination subcutaneous biologic therapy used in oncology settings and is important for accurate drug utilization, administration reporting, and reimbursement for high-cost cancer therapies. Nationally, accurate use of this HCPCS code affects provider billing, payer coverage decisions, and patient access to combined monoclonal antibody regimens.
The analysis covers major national payers including Aetna, Blue Cross Blue Shield, Cigna, UnitedHealthcare, and Medicare. Readers will find an overview of coding and clinical context, payer coverage patterns where available, typical sites of service for administration, and benchmarking considerations for drug-unit reporting. The publication also summarizes common modifiers that may accompany billing for complex drug administrations and highlights where input data is not available.
Intended for revenue cycle leaders, oncology practice managers, and policy analysts, the piece provides concise guidance on what the code represents, how it is used in billing lines, and what information to expect when reconciling claims for combination biologic injections. Data not available in the input is explicitly noted where applicable.
Billing Code Overview
HCPCS Level II code J9316 describes the injection of pertuzumab, trastuzumab, and hyaluronidase-zzxf, per 10 mg. This code represents a combination biologic therapy delivered by injection that includes two monoclonal antibodies (pertuzumab and trastuzumab) formulated with hyaluronidase to facilitate subcutaneous administration.
-
Service type: Drug administration (combination biologic injection)
-
Typical site of service: Outpatient infusion clinic or physician office where parenteral oncology therapies are administered. Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient receiving J9316 is an adult with HER2-positive breast cancer undergoing subcutaneous administration of the fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf as part of systemic therapy. The patient commonly presents to an oncology infusion clinic or outpatient oncology department for scheduled neoadjuvant, adjuvant, or metastatic treatment. The clinical workflow includes verification of the chemotherapy order and dose by the oncologist and oncology pharmacist, confirmation of patient identity and consent, assessment of vitals and cardiac function history (baseline left ventricular ejection fraction), insertion or assessment of existing peripheral IV or port access, administration of pre-medications if protocol requires, timed subcutaneous injection of the combination product, observation for immediate adverse reactions (typically 15–60 minutes), documentation of lot numbers and administered milligrams, and scheduling of follow-up visits and imaging or labs as indicated. Typical sites of service are outpatient hospital infusion centers, physician office oncology suites, and ambulatory infusion centers. Patient scenario example: a 54-year-old woman with newly diagnosed stage II HER2-positive invasive ductal carcinoma receives adjuvant subcutaneous pertuzumab/trastuzumab/hyaluronidase as part of her scheduled triweekly regimen following surgery, with baseline echocardiogram normal and monitoring planned with periodic cardiac surveillance.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 |